Net Cash Provided by (Used in) Investing Activities of Grace Therapeutics, Inc. from 31 Mar 2019 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Summary
Grace Therapeutics, Inc. quarterly and annual Net Cash Provided by (Used in) Investing Activities in USD history and change rate from 31 Mar 2019 to 30 Jun 2025.
  • Grace Therapeutics, Inc. Net Cash Provided by (Used in) Investing Activities for the quarter ending 30 Jun 2025 was $0.
  • Grace Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2024 was $0, a 100% decline from 2023.
  • Grace Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2023 was $104,000, a 99% decline from 2022.
  • Grace Therapeutics, Inc. annual Net Cash Provided by (Used in) Investing Activities for 2022 was $13,153,000.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Investing Activities, Trailing 12 Months (USD)
Net Cash Provided by (Used in) Investing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Investing Activities, Annual (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Annual Change (%)

Grace Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Investing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $0 +$15,000 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2026 Q1
Q2 2024 $15,000 -$15,000 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2026 Q1
Q2 2023 $0 -$13,258,000 -100% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q1
Q2 2022 $16,663,000 $13,258,000 +$20,185,000 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q1
Q1 2022 $3,522,000 $11,000 +$8,428,000 01 Jan 2022 31 Mar 2022 10-K 23 Jun 2023 2023 FY
Q4 2021 $11,950,000 $557,000 +$1,929,000 01 Oct 2021 31 Dec 2021 10-Q 14 Feb 2022 2021 Q3
Q3 2021 $13,879,000 $2,837,000 +$2,870,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2021 2021 Q2
Q2 2021 $16,749,000 $6,927,000 -$6,891,000 -19142% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q1
Q1 2021 $9,858,000 $8,417,000 -$16,555,000 -203% 01 Jan 2021 31 Mar 2021 10-K 21 Jun 2022 2022 FY
Q4 2020 $6,697,000 $1,372,000 -$1,025,000 -295% 01 Oct 2020 31 Dec 2020 10-Q 14 Feb 2022 2021 Q3
Q3 2020 $7,722,000 $33,000 -$3,399,000 -101% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q2
Q2 2020 $11,121,000 $36,000 -$5,554,000 -101% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q1
Q1 2020 $16,675,000 $8,138,000 +$17,580,000 01 Jan 2020 31 Mar 2020 10-K 29 Jun 2020 2020 FY
Q4 2019 $905,000 $347,000 01 Oct 2019 31 Dec 2019 10-Q 09 Feb 2021 2021 Q3
Q3 2019 $3,366,000 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2021 Q2
Q2 2019 $5,518,000 01 Apr 2019 30 Jun 2019 10-Q 13 Aug 2020 2021 Q1
Q1 2019 $9,442,000 01 Jan 2019 31 Mar 2019 10-K 29 Jun 2020 2020 FY

Grace Therapeutics, Inc. Annual Net Cash Provided by (Used in) Investing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $0 -$104,000 -100% 01 Apr 2024 31 Mar 2025 10-K 23 Jun 2025 2025 FY
2023 $104,000 -$13,049,000 -99% 01 Apr 2023 31 Mar 2024 10-K 23 Jun 2025 2025 FY
2022 $13,153,000 +$16,675,000 01 Apr 2022 31 Mar 2023 10-K 21 Jun 2024 2024 FY
2021 $3,522,000 +$6,336,000 +64% 01 Apr 2021 31 Mar 2022 10-K 23 Jun 2023 2023 FY
2020 $9,858,000 -$17,996,000 -221% 01 Apr 2020 31 Mar 2021 10-K 21 Jun 2022 2022 FY
2019 $8,138,000 01 Apr 2019 31 Mar 2020 10-K 22 Jun 2021 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.